Retinitis Pigmentosa Clinical Trial
Official title:
Natural History Study in Retinitis Pigmentosa Caused by Mutations in the BEST1 Gene
The purpose of this study is to establish the natural history of of participants with BESTROPHIN 1 Vitelliform Macular Dystrophy. The blinding disorder Best Vitelliform Macular Dystrophy (VMD) is caused by any one of more than 250 different mutations in the BEST1 gene. As new treatments are developed, a clear understanding of the natural history of disease progression of BEST1 VMD is necessary. The goals of this natural history study are to: 1. Report the natural history of retinal degeneration in participants with a clinical diagnosis of VMD with molecular confirmation of a pathogenic BEST1 mutation(s). 2. Identify sensitive structural and functional outcome measures to use for future multicenter clinical trials for the treatment of BESTROPHIN 1 VMD. 3. Compare progression of the identified structural and functional measures between the two eyes to judge the suitability of the second untreated eye as a control for a future clinical trial involving unilateral treatment 4. Identify well-defined patient populations for future clinical trials of investigative treatments for BEST1 VMD.
| Status | Recruiting |
| Enrollment | 52 |
| Est. completion date | May 31, 2025 |
| Est. primary completion date | May 31, 2025 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility | Inclusion Criteria: - Ability to provide informed consent - Diagnosis of BEST1-associated VMD by study physician, who are trained retinal specialists in the university clinic Must be able to commit to 4 follow-up study visits (3 years) Exclusion Criteria: - Systemic condition that prevents the participant from undergoing the exams |
| Country | Name | City | State |
|---|---|---|---|
| France | Institut de la Vision/Centre de maladies rares du Centre Hospitalier National Ophtalmologique des Quinze-Vingts | Paris | |
| Germany | Eberhard Karls University Tubingen | Tuebingen | |
| United States | Columbia University Irving Medical Center | New York | New York |
| Lead Sponsor | Collaborator |
|---|---|
| Columbia University | Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, National Eye Institute (NEI), Universität Tübingen |
United States, France, Germany,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Medmont Dark Adapted Chromatic (DAC) Automated Perimeter | Up to 3 years | ||
| Primary | Full-field electroretinogram (ERG) | ERG conducted under International Society for Clinical Electrophysiology of Vision (ISCEV) Protocol. | Up to 3 years | |
| Primary | Electroocoulogram (EOG) | EOG conducted under International Society for Clinical Electrophysiology of Vision (ISCEV) Protocol | Up to 3 years | |
| Primary | Optical Coherence Tomography (OCT) | Up to 3 years | ||
| Primary | Fundus Autofluorescence (FAF) | Up to 3 years | ||
| Primary | Near-infrared fundus autofluorescence (NIR-AF) | Up to 3 years | ||
| Primary | Quantitative Fundus Autofluorescence (qAF) | Up to 3 years | ||
| Secondary | Best-corrected Visual Acuity (BCVA) | Up to 3 years | ||
| Secondary | Color Fundus Photos | Up to 3 years | ||
| Secondary | Macular Integrity Assessment (MAIA) Microperimetry | Up to 3 years | ||
| Secondary | Goldman Kinetic Visual Field | Up to 3 years | ||
| Secondary | Light-adapted Static Perimetry | Up to 3 years | ||
| Secondary | Dark-adapted Chromatic Perimetry | Up to 3 years | ||
| Secondary | Full-field Stimulus Testing | Up to 3 years |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01432847 -
Cell Collection to Study Eye Diseases
|
||
| Completed |
NCT04983914 -
Retrospective NIS to Evaluate the Patient Benefit of TES
|
||
| Recruiting |
NCT03845218 -
Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
|
||
| Completed |
NCT00231010 -
Molecular Genetics of Retinal Degenerations
|
||
| Active, not recruiting |
NCT04611503 -
PDE6A Gene Therapy for Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
| Completed |
NCT02909985 -
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
|
N/A | |
| Recruiting |
NCT01914913 -
Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
| Completed |
NCT01949623 -
Biomarkers In Retinitis Pigmentosa (BIRP)
|
N/A | |
| Completed |
NCT01835002 -
Transcorneal Electrical Stimulation - Multicenter Safety Study
|
N/A | |
| Completed |
NCT00407602 -
Argus® II Retinal Stimulation System Feasibility Protocol
|
N/A | |
| Completed |
NCT00515814 -
Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors
|
N/A | |
| Completed |
NCT00100230 -
DHA and X-Linked Retinitis Pigmentosa
|
Phase 2 | |
| Active, not recruiting |
NCT00378742 -
Repository for Inherited Eye Diseases
|
||
| Terminated |
NCT05085964 -
An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
|
Phase 2 | |
| Recruiting |
NCT05805007 -
Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa
|
Early Phase 1 | |
| Recruiting |
NCT05909488 -
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06291935 -
Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene
|
Phase 1 | |
| Recruiting |
NCT03078309 -
The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients
|
Early Phase 1 | |
| Completed |
NCT04238858 -
Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa
|
N/A | |
| Active, not recruiting |
NCT01680510 -
The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil
|
Phase 1/Phase 2 |